Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2016

01.01.2016 | original article

Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients

verfasst von: MD Efnan Algin, Ahmet Ozet, Ozge Gumusay, Guldal Yilmaz, Suleyman Buyukberber, Ugur Coskun, Meltem Baykara, Bulent Cetin, Ramazan Yıldız, Mustafa Benekli

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

In this retrospective study, we aimed to evaluate the clinicopathological characteristics of the patients presenting with liver metastases from unknown primary site besides survival rates, treatment outcomes, and prognostic factors.

Methods

In all, 68 patients followed-up at our center with adenocarcinoma of unknown primary (ACUP) metastatic to the liver between 2005 and 2013 were enrolled. All of the liver metastases were proven by liver biopsy and all yielded diagnosis of adenocarcinoma.

Results

Median age was 61 years (29–90) and most of the patients were male (male/female: 43/25). The liver was the only metastatic site in 2 (3 %) patients whilst 66 patients (97 %) had extrahepatic metastases. The most common extrahepatic metastatic sites were lymph nodes (89.7 %), lungs (32.4 %), bones (25 %), peritoneum (11.8 %), brain (4.4 %), and adrenal glands (2.9 %). Of all 68 patients, 39 (57.4 %) were treated with chemotherapy. Median overall survival (OS) was significantly higher in ACUP patients treated with chemotherapy [12.5 months (95 % CI 8.3–16.7) vs. 4 months (95 % CI 1.2–6.8), (p = 0.026), respectively]. In multivariate analysis, ECOG (Eastern Cooperative Oncology Group) performance status (p = 0.009), chemotherapy (p = 0.024), serum albumin (p = 0.012), and serum CA 19-9 level (p = 0.026) at initial diagnosis were identified as independent prognostic factors influencing survival for the patients with liver metastases from ACUP.

Conclusion

Patients with liver metastases from ACUP have poor prognosis and chemotherapy improves survival. Decreased serum albumin level, increased CA 19-9 level and poor performance status are independent poor prognostic factors.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257–63. CrossRefPubMed Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257–63. CrossRefPubMed
2.
3.
Zurück zum Zitat Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol. 2003;14 Suppl 3:iii11–18. PubMed Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol. 2003;14 Suppl 3:iii11–18. PubMed
4.
Zurück zum Zitat Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005. CrossRefPubMed Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005. CrossRefPubMed
5.
Zurück zum Zitat Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998;16(6):2105–12. PubMed Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998;16(6):2105–12. PubMed
6.
Zurück zum Zitat Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary. Cancer Treat Rev. 2008;34:693–700. CrossRefPubMed Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary. Cancer Treat Rev. 2008;34:693–700. CrossRefPubMed
7.
Zurück zum Zitat Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M. Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol. 2005;29:1224–32. CrossRefPubMed Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M. Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol. 2005;29:1224–32. CrossRefPubMed
8.
Zurück zum Zitat Hogan BA, Thornton FJ, Brannigan M, et al. Hepatic metastases from an unknown primary neoplasm: survivall, prognostic indicators and value of extensive investigations. Clin Radiol. 2002;57:1073–7. CrossRefPubMed Hogan BA, Thornton FJ, Brannigan M, et al. Hepatic metastases from an unknown primary neoplasm: survivall, prognostic indicators and value of extensive investigations. Clin Radiol. 2002;57:1073–7. CrossRefPubMed
9.
Zurück zum Zitat Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272–80. PubMed Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272–80. PubMed
10.
Zurück zum Zitat Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243–50. CrossRefPubMed Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243–50. CrossRefPubMed
12.
Zurück zum Zitat Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003;89 Suppl 1:S59–66. PubMedCentralCrossRefPubMed Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003;89 Suppl 1:S59–66. PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N. Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012;84:213–23. CrossRefPubMed Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N. Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012;84:213–23. CrossRefPubMed
14.
Zurück zum Zitat Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651–6. CrossRefPubMed Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651–6. CrossRefPubMed
15.
Zurück zum Zitat Greco FA, Burris HA, Erland JB, et al. Carcinoma of unknown primary site. Cancer. 2000;89:2655–60. CrossRefPubMed Greco FA, Burris HA, Erland JB, et al. Carcinoma of unknown primary site. Cancer. 2000;89:2655–60. CrossRefPubMed
16.
Zurück zum Zitat Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist. 2004;9:644–52. CrossRefPubMed Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist. 2004;9:644–52. CrossRefPubMed
17.
Zurück zum Zitat Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11:211–5. CrossRefPubMed Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11:211–5. CrossRefPubMed
18.
Zurück zum Zitat Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L. Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn Interv Radiol. 2009;15:297–302. PubMed Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L. Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn Interv Radiol. 2009;15:297–302. PubMed
19.
Zurück zum Zitat Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2009;69:271–8. CrossRefPubMed Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2009;69:271–8. CrossRefPubMed
20.
Zurück zum Zitat Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol. 1986;4:1652–7. PubMed Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol. 1986;4:1652–7. PubMed
21.
Zurück zum Zitat Seve P, Coquard IR, Lenoir VT, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 2006;107:2698–705. CrossRefPubMed Seve P, Coquard IR, Lenoir VT, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 2006;107:2698–705. CrossRefPubMed
Metadaten
Titel
Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients
verfasst von
MD Efnan Algin
Ahmet Ozet
Ozge Gumusay
Guldal Yilmaz
Suleyman Buyukberber
Ugur Coskun
Meltem Baykara
Bulent Cetin
Ramazan Yıldız
Mustafa Benekli
Publikationsdatum
01.01.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0858-8